Navigation Links
QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy
Date:5/22/2008

Establishes Preferred Dose for Optimal Efficacy and Tolerability; Study Goals and Secondary Endpoints Met

SYDNEY, Australia and BEDMINSTER, N.J., May 22 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today additional Phase 3 data for Q8003IR establishing a 12mg/8mg morphine and oxycodone combination as the preferred dose for optimal efficacy and tolerability.

"While the initial Phase 3 efficacy data demonstrated statistically significant pain reduction activity of Q8003IR at all dose levels, further analysis suggests that the 12mg/8mg dose delivers the best analgesic effect and tolerability profile," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "These data confirm that our patented dual opioid combination of morphine and oxycodone provides synergistic effects on pain relief and is able to achieve equal or better analgesia at materially lower doses than the active opioid comparator while simultaneously reducing incidence levels of specific side effects."

The goal of the double-blind, placebo-controlled Phase 3 study was to compare four different dosage regimens of Q8003IR in patients with moderate to severe post-surgery pain (bunionectomy) and establish the preferred dose parameters. Secondary endpoints included: (1) efficacy relating to the time to onset of analgesia and the duration of effect from a single oral dose and (2) safety as measured by the incidence and intensity of opioid-related adverse events.

Of the patients receiving 12mg/8mg dose of morphine/oxycodone, 58% reported good to excellent global improvement (as compared to 13% for placebo) and demonstrated the greatest dose-response effect (p<0.0003) in terms of reducing pain intensity scores as well as other measures of analgesic effect.

Post-
'/>"/>

SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
2. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
3. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
4. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
5. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
6. Immunosyn Corporation Releases SF-1019 Study Results
7. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
8. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
(Date:12/19/2014)... Friday, December 19 edition of USA ... features Konica Minolta, the company announced today. The supplement will focus ... organizations. In addition to the print section that ... New York , Chicago , ... Minneapolis and San Francisco , a ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2
... Texas , May 5 HealthTronics, Inc. (Nasdaq: ... services, today announced that it has signed a definitive merger ... which Endo will acquire HealthTronics.  Under the terms of the ... to acquire all of the outstanding shares of HealthTronics common ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... filed an Abbreviated New Drug Application (ANDA) with the ... market a raloxifene hydrochloride tablet.  Watson,s raloxifene hydrochloride tablet ... ® is indicated for the treatment and prevention of ...
Cached Medicine Technology:HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 2HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 3HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 4HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 5HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 6HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 7Watson Confirms EVISTA(R) Patent Challenge 2Watson Confirms EVISTA(R) Patent Challenge 3
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley ... to provide logistics and support for one of Dallas’ ... a long history of giving back to the community in ... year's Toy Drive were Whataburger® and 99.5 The Wolf. , ... holidays. Providing gifts to children who would otherwise not receive ...
(Date:12/22/2014)... 21, 2014 A substantial percentage ... computed tomography (CT) to evaluate abnormal findings on ... cancer, according to a new study published online ... the findings show that radiologist recommendations for additional ... to patient care. , RAIs, which have grown ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 In ... is segmented by power source, product, and application. ... electric-powered, battery-powered, and pneumatic instruments. By product, the ... and accessories segments. The handpieces market is further ... devices, suction coagulators, laparoscopic instruments, shavers, wire/pin drivers, ...
(Date:12/21/2014)... 2014 Khanna Vision Institute is pleased ... the Aspen Helicopters holiday event for underprivileged kids. The ... sleigh, flown by an aspen helicopter pilot. In the ... with sleigh was visible.(please see accompanying video). Helicopter pilots ... has helped many pilots with Pi in eye vision ...
Breaking Medicine News(10 mins):Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... chromosomes can break and reshuffle pieces of themselves is nothing ... cells. The rules for where chromosomes are likely to break ... now starting to come into view. Researchers at Children,s Hospital ... those rules into clearer focus by discovering that where each ...
... PHILADELPHIA -- In an effort to reduce and eventually eliminate ... Kimmel Cancer Center at Jefferson has established the ... P. Mitchell, M.D., FACP , a medical oncologist at ... and Medical Oncology in the Department of Medical Oncology at ...
... 16 (HealthDay News) -- About 7.5 million American children under ... with alcohol abuse over the past year, a new government ... across the country, say researchers at the Substance Abuse and ... "The enormity of this public health problem goes well ...
... Feb. 16 (HealthDay News) -- Researchers have sequenced the genomes ... transmissible facial cancer that threatens the species with extinction. ... found only on the Australian island of Tasmania, according to ... Cell . "There are targeted drugs that work ...
... painACTION.com is a free, non-promotional online program designed ... people with chronic pain. This study tested painACTION.com,s ... in people with chronic migraine headaches. A total ... to painACTION.com were more confident that they could ...
... JOLLA,CA -- Drugs targeting an enzyme involved in inflammation might ... to a new study by scientists at the Salk Institute ... activity of the enzyme IKK2, which helps activate the body,s ... lung cancer and increased their lifespan. The findings, ...
Cached Medicine News:Health News:To understand chromosome reshuffling, look to the genome's 3D structure 2Health News:To understand chromosome reshuffling, look to the genome's 3D structure 3Health News:To understand chromosome reshuffling, look to the genome's 3D structure 4Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 2Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 3Health News:Genome Map Might Help Save Tasmanian Devil From Extinction 2Health News:painACTION.com improves migraine self-management and reduces migraine-related psychological distress 2Health News:Salk researchers find new drug target for lung cancer 2Health News:Salk researchers find new drug target for lung cancer 3
... high-power, long-pulse Nd:YAG technology provides practitioners with the ... lesions and perform permanent hair reduction on all ... size feature allows the practitioner to instantly switch ... spot size with a simple twist of the ...
...
...
... is your system. CONMED's family of products ... New, state-of-the art generators feature proprietary Energy ... continuous synchronization of current and voltage in ... enables the system to sample current and ...
Medicine Products: